Impact of daratumumab-based induction on stem cell collection parameters in Swedish myeloma patients-Reference-Cited by-同舟云学术

Impact of daratumumab-based induction on stem cell collection parameters in Swedish myeloma patients

Published:2022-10-06 Issue:2 Volume:108 Page:610-614
ISSN:1592-8721
Container-title:Haematologica
language:
Short-container-title:haematol

Author:

Lemonakis Konstantinos,Tatting Love,Lisak Mikael,Carlson Kristina,Crafoord Jacob,Blimark Cecilie H,Santamaria Antonio I,Wichert Stina,Lenhoff Stig,Hansson Markus

Publisher

Ferrata Storti Foundation (Haematologica)

Subject

Hematology

Reference14 articles.

1. Cavo M, Gay F, Beksac M. Autologous haematopoietic stem-cell transplantation versus bortezomib-melphalan-prednisone, with or without bortezomib-lenalidomide-dexamethasone consolidation therapy, and lenalidomide maintenance for newly diagnosed multiple myeloma (EMN02/HO95): a multicentre, randomised, open-label, phase 3 study. Lancet Haematol. 2020; 7(6):e456-e468.

2. Attal M, Lauwers-Cances V, Hulin C. Lenalidomide, bortezomib, and dexamethasone with transplantation for myeloma. N Engl J Med. 2017; 376(14):1311-1320.

3. Moreau P, Attal M, Hulin C. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study [published correction appears in Lancet. 2019 Jun 14;:]. Lancet. 2019; 394(10192):29-38.

4. Voorhees PM, Kaufman JL, Laubach J. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: the GRIFFIN trial. Blood. 2020; 136(8):936-945.

5. Giralt S, Costa L, Schriber J. Optimizing autologous stem cell mobilization strategies to improve patient outcomes: consensus guidelines and recommendations. Biol Blood Marrow Transplant. 2014; 20(3):295-308.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Impact of Anti-CD38 Monoclonal Antibody Therapy on CD34+ Hematopoietic Stem Cell Mobilization, Collection, and Engraftment in Multiple Myeloma Patients—A Systematic Review;Pharmaceuticals;2024-07-15

2. Anti-CD38 monoclonal antibody impairs CD34+mobilization and affects clonogenic potential in multiple myeloma patients;BLOOD TRANSFUS-ITALY;2024

3. Predictive factors for peripheral blood stem cell mobilization in multiple myeloma in the era of novel therapies: A single‐center experience;Cancer Medicine;2024-06

4. Daratumumab during Myeloma Induction Therapy Is Associated with Impaired Stem Cell Mobilization and Prolonged Post-Transplant Hematologic Recovery;Cancers;2024-05-13

5. Impact of the Addition of Daratumumab to the Standard Bortezomib-Thalidomide-Dexamethasone Regimen on Hematopoietic Stem Cell Mobilization and Collection, Post-Transplant Engraftment and Infectious Complications: A Case-Control Multicentre Real-Life Analy;Mediterranean Journal of Hematology and Infectious Diseases;2024-04-30